Key facts
- Duo Oncology’s last known valuation is $25.0M.
- It has raised $13.1M across 3 recorded rounds; the latest was Seed Round ($1.4M) in Jun 2025.
- Notable investors include Innovation Works, Ulu Ventures, SeedFolio, BeOne Medicines, LifeX Ventures — 10 tracked in total.
- Duo Oncology has filed 4 Form Ds with the SEC since 2021, most recently Jun 2025 ($400K sold to 8 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Duo Oncology
Funding rounds
3 roundsAbout Duo Oncology
Developer of a clinical-stage biotechnology platform designed to replace traditional chemotherapy with more precise and tolerable cancer treatments. The company offers targeted, next-generation cancer therapies with reduced toxicity and improved selectivity, enabling patients with aggressive cancers to receive effective treatment with fewer debilitating side effects.
- Sector
- Healthcare
- HQ
- Pittsburgh, PA, United States
- Founded
- 2020
- Employees
- 8
- Website
- duooncology.com/
- Ownership
- Privately Held (backing)
Duo Oncology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Duo Oncology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Duo Oncology in its N-PORT filings yet. We sweep new filings monthly.